Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-11-05
2008-09-02
Chen, Stacy B (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S218100
Reexamination Certificate
active
07419789
ABSTRACT:
The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5498538 (1996-03-01), Kay et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5625033 (1997-04-01), Kay et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5667988 (1997-09-01), Barbas et al.
patent: 6165477 (2000-12-01), Ivy et al.
patent: 6391567 (2002-05-01), Littman et al.
patent: 1046651 (2000-10-01), None
patent: WO 91/05876 (1991-05-01), None
patent: WO 93/01820 (1993-02-01), None
patent: WO 00/63251 (2000-10-01), None
patent: WO 01/64752 (2001-09-01), None
patent: WO 02/080851 (2002-10-01), None
Desrosiers, R. Prospects for an AIDS vaccine, Nature Medicine, 2004, 10(3):221-223.
Feinburg et al. AIDS vaccine models: challenging challenge viruses, Nature Medicine, 2002, 8(3):207-210.
Greene, W. The brightening future of HIV therapeutics, Nature Immunology, 2004, 5(9):867-871.
Leyssen et al. Perspectives for the Treatment of Infections with Flaviviridae, Clinical Microbiology Reviews, 2000, 13(1):67-82.
Centers for Disease Control Dengue Fever Home Page, website last updated 2003 http://www.cdc.gov
cidod/dvbid/dengue/index.htm.
Tassaneetrithep et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells, Journal of Experimental Medicine, Apr. 2003, 197(7):823-829.
Men et al. Identification of Chimpanzee Fab Fragments, Journal of Virology, 2004, 78(9):4665-4674.
Brandriss et al. Lethal 17D Yellow Fever Encephalitis in Mice, Journal of General Virology, 1986, 67:229-234.
Curtis, Benson M. et al., “Sequence and Expression of a Membrane-Associated C-type Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein gp120,”Proc. Natl. Acad. Sci. USA, vol. 89, pp. 8356-8360 (1992).
Geijtenbeek, Teunis B.H. et al., “Identification of DC-Sign, a Novel Dendritic Cell-Specific ICAM-3 Receptor that Supports Primary Immune Responses,”Cell, vol. 100, pp. 575-585 (2000).
Halary, Franck et al., “Human Cytomegalovirus Binding to DC-Sign is Required for Dendritic Cell Infection and Target Celltrans-Infection,”Immunuty, vol. 17, pp. 653-664 (2002).
Tailleux, Ludovic et al., “DC-Sign is the Major Mycobacterium Tuberculosis Receptor on Human Dendritic Cells,”The Journal of Experimental Medicine, vol. 197, pp. 121-127 (2003).
Desrosiers, R., “Prospects for an AIDS Vaccine,”Nature Medicine, 10(3):221-233 (2004).
Feinberg et al, “AIDS Vaccine Models: Challenging Challenge Viruses,”Nature Medicine, 9(3):207-210 (2002).
Greene, W., “The Brightening Future of HIV Therapeutics,”Nature Immunology, 4(9):867-871 (2004).
Halary et al.; “Human Cytomegalovirus Binding to DC-Sign is Required for Dendritic Cell Infection and Target CellTrans-Infection”; Immunity, vol. 17, No. 5, pp. 653-664, (2002).
Kwon et al.; “DC-Sign-Mediated Internalization of HIV is Required forTrans-Enhancement of T Cell Infection”;Immunity, vol. 16, No. 1, pp. 135-144, (2002).
MacDonald et al., “Mucosal and Parenteral Vaccination Against Acute and Latent MCMV,”J. Virology, 72(1):442-451 (1998).
Navarro-Sanchez et al.; “Dendritic-Cell-Specific ICAM3-Grabbing Non-Integrin is Essential for the Productive Infection of Human Dendritic Cells by Mosquito-Cell-Derived Dengue Viruses”; EMBO Reports, vol. 4, No. 7, pp. 723-728, (2003).
Tassaneetrithep et al.; “DC-Sing (CD209) Mediates Dengue Virus Infection of Human Dendritic Cells”l Journal of Experimental Medicine, vol. 197, No. 7, pp. 823-829, (2003).
Wang et al., Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B,J. Virology, 78(8):3965-3976 (2004).
Office Action dated Dec. 28, 2004 in U.S. Appl. No. 10/700,507.
Office Action dated Oct. 17, 2005 in U.S. Appl. No. 10/700,507.
U.S. Appl. No. 10/464,531 of Olivier Neyrolles, Olivier Schwartz, Ludovic Tailleux , and Phillippe LaGrange, filed Jun. 19, 2003.
U.S. Appl. No. 10/700,507 of Ali Amara, Frank Halary, Julie Dechanet-Merville, Jean-Francois Moreau, Fernando Arenzana-Seisdedos and Thierry Delaunay, filed Nov. 5, 2003.
WO 2004/041299 A1 published May 21, 2004, which entered the National Stage in U.S. Appl. No. 10/533,924.
Office Action mailed Jun. 26, 2006, in U.S. Appl. No. 10/700,507, which was filed Nov. 5, 2003.
Amara Ali
Arenzana-Seisdedos Fernando
Despres Philippe
Virelizier Jean-Louis
Chen Stacy B
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Institut Pasteur
LandOfFree
Method of inhibiting binding of Dengue virus to a human cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting binding of Dengue virus to a human cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting binding of Dengue virus to a human cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3986245